Cargando…

Suberoylanilide hydroxamic acid (SAHA) inhibits transforming growth factor-beta 2-induced increases in aqueous humor outflow resistance

Transforming growth factor-beta 2 (TGF-β2) is highly concentrated in the aqueous humor of primary open-angle glaucoma patients. TGF-β2 causes fibrosis of outflow tissues, such as the trabecular meshwork (TM), and increases intraocular pressure by increasing resistance to aqueous humor outflow. Recen...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fujimoto, Tomokazu, Inoue-Mochita, Miyuki, Iraha, Satoshi, Tanihara, Hidenobu, Inoue, Toshihiro
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Biochemistry and Molecular Biology 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406002/ https://www.ncbi.nlm.nih.gov/pubmed/34389355 http://dx.doi.org/10.1016/j.jbc.2021.101070

Ejemplares similares

Vascular Endothelial Growth Factor-A Increases the Aqueous Humor Outflow Facility
por: Fujimoto, Tomokazu, et al.
Publicado: (2016)

A ROCK inhibitor suppresses the transforming growth factor-beta-2-induced endothelial–mesenchymal transition in Schlemm’s canal endothelial cells
por: Fujimoto, Tomokazu, et al.
Publicado: (2023)

Suberoylanilide Hydroxamic Acid (SAHA) Is a Driver Molecule of Neuroplasticity: Implication for Neurological Diseases
por: Verrillo, Lucia, et al.
Publicado: (2023)

Oxidative stress response signaling pathways in trabecular meshwork cells and their effects on cell viability
por: Awai-Kasaoka, Nanako, et al.
Publicado: (2013)

p38 MAP Kinase Inhibitor Suppresses Transforming Growth Factor-β2–Induced Type 1 Collagen Production in Trabecular Meshwork Cells
por: Inoue-Mochita, Miyuki, et al.
Publicado: (2015)

Correction: TGF-β-induced activation of conjunctival fibroblasts is modulated by FGF-2 and substratum stiffness
por: Matsumura, Tomoyo, et al.
Publicado: (2021)

DNA methyltransferase inhibitor suppresses fibrogenetic changes in human conjunctival fibroblasts
por: Yonemura, Hitomi, et al.
Publicado: (2019)

Inhibition of Rho Kinase Induces Antioxidative Molecules and Suppresses Reactive Oxidative Species in Trabecular Meshwork Cells
por: Fujimoto, Tomokazu, et al.
Publicado: (2017)

In silico modification of suberoylanilide hydroxamic acid (SAHA) as potential inhibitor for class II histone deacetylase (HDAC)
por: Tambunan, Usman SF, et al.
Publicado: (2011)

Effects of Suberoylanilide Hydroxamic Acid (SAHA) on the Inflammatory Response in Lipopolysaccharide-Induced N9 Microglial Cells
por: Çelik, Zülfinaz Betül, et al.
Publicado: (2022)

The Anti-Tumor Effects and Molecular Mechanisms of Suberoylanilide Hydroxamic Acid (SAHA) on the Aggressive Phenotypes of Ovarian Carcinoma Cells
por: Chen, Shuo, et al.
Publicado: (2013)

Suberoylanilide Hydroxamic Acid (SAHA) Treatment Reveals Crosstalk Among Proteome, Phosphoproteome, and Acetylome in Nasopharyngeal Carcinoma Cells
por: Huang, Huichao, et al.
Publicado: (2022)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid (SAHA) Restores Cardiomyocyte Contractility in a Rat Model of Early Diabetes
por: Bocchi, Leonardo, et al.
Publicado: (2019)

TGF-β-induced activation of conjunctival fibroblasts is modulated by FGF-2 and substratum stiffness
por: Matsumura, Tomoyo, et al.
Publicado: (2020)

Effects of suberoylanilide hydroxamic acid (SAHA) combined with paclitaxel (PTX) on paclitaxel-resistant ovarian cancer cells and insights into the underlying mechanisms
por: Liu, Zhaohui, et al.
Publicado: (2014)

Transcriptional profiling of suberoylanilide hydroxamic acid (SAHA) regulated genes in mineralizing dental pulp cells at early and late time points
por: Duncan, Henry F., et al.
Publicado: (2015)

Suberoylanilide hydroxamic acid (SAHA) reverses chemoresistance in head and neck cancer cells by targeting cancer stem cells via the downregulation of nanog
por: Kumar, Bhavna, et al.
Publicado: (2015)

HDACi Valproic Acid (VPA) and Suberoylanilide Hydroxamic Acid (SAHA) Delay but Fail to Protect against Warm Hepatic Ischemia-Reperfusion Injury
por: Ruess, Dietrich A., et al.
Publicado: (2016)

The in vitro and vivo anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) and MG132 on the aggressive phenotypes of gastric cancer cells
por: Lu, Hang, et al.
Publicado: (2016)

Comparative evaluation of the treatment efficacy of suberoylanilide hydroxamic acid (SAHA) and paclitaxel in ovarian cancer cell lines and primary ovarian cancer cells from patients
por: Sonnemann, Jürgen, et al.
Publicado: (2006)

Effects of Treatment with Suppressive Combination Antiretroviral Drug Therapy and the Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid; (SAHA) on SIV-Infected Chinese Rhesus Macaques
por: Ling, Binhua, et al.
Publicado: (2014)

Molecular dynamics simulation of complex Histones Deacetylase (HDAC) Class II Homo Sapiens with suberoylanilide hydroxamic acid (SAHA) and its derivatives as inhibitors of cervical cancer
por: Tambunan, Usman Sumo Friend, et al.
Publicado: (2013)

Mechanisms of suberoylanilide hydroxamic acid inhibition of mammary cell growth
por: Said, Thenaa K, et al.
Publicado: (2001)

Suberoylanilide hydroxamic acid represses glioma stem-like cells
por: Hsu, Che-Chia, et al.
Publicado: (2016)

ING5‐mediated antineuroblastoma effects of suberoylanilide hydroxamic acid
por: Wu, Ji‐cheng, et al.
Publicado: (2018)

Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway
por: Shi, Xuan-Yan, et al.
Publicado: (2017)

Histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), enhances anti-tumor effects of the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib in triple-negative breast cancer cells
por: Min, Ahrum, et al.
Publicado: (2015)

A Novel Osteogenic Activity of Suberoylanilide Hydroxamic Acid is Synergized by BMP-2
por: Lee, Zang Hee, et al.
Publicado: (2015)

The Histone Deacetylase Inhibitor Suberoylanilide Hydroxamic Acid Alleviates Salinity Stress in Cassava
por: Patanun, Onsaya, et al.
Publicado: (2017)

Data on early postoperative changes in aqueous monocyte chemoattractant protein-1 levels after phacoemulsification
por: Kawai, Motofumi, et al.
Publicado: (2016)

Clinical and laboratory experience of vorinostat (suberoylanilide hydroxamic acid) in the treatment of cutaneous T-cell lymphoma
por: Duvic, M, et al.
Publicado: (2006)

Factors Influencing Aqueous Proinflammatory Cytokines and Growth Factors in Uveitic Glaucoma
por: Ohira, Saori, et al.
Publicado: (2016)

Modulating Ocular Scarring in Glaucoma Filtration Surgery Using the Epigenetic Adjunct Suberoylanilide Hydroxamic Acid
por: Rodgers, Cooper D, et al.
Publicado: (2019)

Clinical experience with the novel histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid) in patients with relapsed lymphoma
por: O'Connor, O A
Publicado: (2006)

The histone deacetylase inhibitor suberoylanilide hydroxamic acid attenuates human astrocyte neurotoxicity induced by interferon-γ
por: Klegeris, Andis, et al.
Publicado: (2012)

Chlorinated Polyketide Obtained from a Daldinia sp. Treated with the Epigenetic Modifier Suberoylanilide Hydroxamic Acid
por: Du, Lin, et al.
Publicado: (2014)

Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, attenuates postoperative cognitive dysfunction in aging mice
por: Jia, Min, et al.
Publicado: (2015)

Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin‐related protein 14‐mediated autophagy
por: Zhen, Zijun, et al.
Publicado: (2017)

Suberoylanilide hydroxamic acid upregulates reticulophagy receptor expression and promotes cell death in hepatocellular carcinoma cells
por: Li, Jia-Yao, et al.
Publicado: (2023)

α,ß-Didehydrosuberoylanilide hydroxamic acid (DDSAHA) as precursor and possible analogue of the anticancer drug SAHA
por: Chattopadhyay, Shital K, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_c9hvohlj0n1nib7fp6ovpc48am